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Zacharias G Laoutidis1,2* and Klaus Mathiak1,3,4Abstract
Background: Over the past thirty years a number of studies have suggested that antidepressants can be effective
in the treatment of depressive symptoms in patients with cancer. The aim of this paper was to review randomized
controlled trials (RCTs) and to perform a meta-analysis in order to quantify their overall effect.
Methods: Pubmed and the Cochrane libraries were searched for the time period between 1980 and 2010.
Results: Nine RCTs were identified and reviewed. Six of them (with a total of 563 patients) fulfilled the criteria for
meta-analysis, but exhibited an unclear risk for bias. The estimated effect size was 1.56 with 95% CI: 1.07- 2.28
(p= 0.021). There were no differences in discontinuation rates between antidepressants and placebo groups
(RR= 0.86 with 95% CI 0.47- 1.56, p=0.62).
Conclusions: This meta-analysis suggests that antidepressants can be effective in treating depressive symptoms
beside clinical depression. When considering the risk of side effects and interactions and the heterogeneity among
the mostly small studies, a general recommendation cannot be made until well-controlled studies are conducted.
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The role of depression in physical illness has been recog-
nized and addressed by many authors. Up to one third of
physically ill patients attending hospital have depressive
symptoms. The diseases with the highest prevalence of
major depression have been reported as follows (from
higher to lower incidence): inflammatory bowel disease,
multiple sclerosis, epilepsy, asthma, back problems, cancer,
COPD, migraine, rheumatic arthritis, stroke, Parkinson’s
disease, diabetes mellitus, and heart disease [1]. Over the
last several years, there has been a growing interest for the
psychological aspects of cancer due to its severe impact on
quality of life (QOL) [2,3]. Physical symptoms that are as-
sociated with both depression and cancer can be a
confounding factor in the assessment of depression in this
population [4]. Several studies evaluated the efficacy of* Correspondence: Zacharias.Laoutidis@lvr.de
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distribution, and reproduction in any mediumpsychological and pharmacological interventions in the
treatment of depression. The psychopharmacological inter-
ventions and particularly the use of antidepressants are sys-
tematically reviewed here and meta-analytical methods are
applied to quantify their overall effect.
Cancer is associated with depression and depressive
symptoms. A meta-analysis by Mitchel et al. [5] included
94 studies and found that the pooled prevalence of
major depression in palliative care settings and haemato-
oncological settings was equal to 16.5% (95% CI: 13.1-
20.3%) and 16.3% (95% CI: 13.4-19.5%), respectively.
Restricting the analysis to standardized clinical assess-
ment, Ng and colleagues [6] found a prevalence of 10.8%
and also a substantial amount of heterogeneity. Even
though these rates appear to be high, a consistent diffe-
rence to a systematically matched sample from general
population data is still controversial. The existing data
suggest that “survivorship presents ongoing psycho-
logical challenges” [7].
There are two main confounding factors in the assess-
ment of depression in cancer patients. First, the distinctiond Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Laoutidis and Mathiak BMC Psychiatry 2013, 13:140 Page 2 of 21
http://www.biomedcentral.com/1471-244X/13/140between normal sadness or grief and symptoms indicating
a depressive episode is not well-defined. Indeed, a phase of
reduced mood or depression is considered part of healthy
coping with grief (e.g. Kübler-Ross already in 1969 [8]).
Further, such reaction patterns may recur as the disease
progresses, by treatment failure, or by findings of metasta-
ses. Therefore, also time criteria may not capture the dy-
namics of disease progression.
A second confounder is the lack of specificity of the de-
pressive symptoms. The ICD-10 and DSM-IV criteria for
depressive episode include symptoms that are often present
in patients with cancer as well, e.g. loss of appetite, low en-
ergy levels, or sleep disturbance. Therefore, the definition
of depression in cancer patients and in physical illness is
ambiguous [4]. It is suggested to identify the patients by
their symptoms and not by a clinical syndrome because the
ability to detect cases of depressive episode or disorder may
be less important than the ability to detect depressive
symptoms remediable to treatment [9]. Several approaches
have been developed to solve the problem of diagnosing
depression in cancer patients [10]. For instance, the substi-
tutive approach suggests that all physical/somatic symp-
toms (change in appetite/weight, sleep disturbance, fatigue,
loss of energy, diminished ability to think or concentrate)
are replaced by non-somatic symptoms (tearfulness, de-
pressed appearance, social withdrawal, decreased talkative-
ness, brooding, self-pity, pessimism, lack of reactivity,
blunting) [11]. These are known as the Endicott criteria.
Therefore, established criteria for depression may not be
better suited to detect therapeutic indications in cancer pa-
tients than the presence of depressive symptoms.
Many guidelines for the treatment of cancer recom-
mend that all cancer patients should be screened for de-
pression, pain, and fatigue (e.g. by the National Institute
of Health [12]). Multi-item scales are used for screening
and diagnosing depression. Quantified results are used
to specify the illness severity and to monitor the course
of the disease. For detecting depression, ultra brief
screening tools have been developed and proven to be
reliable. For instance, Chochinov reported that the single
question: “Are you depressed?” can be a reliable screen-
ing tool [13]. There is clear evidence that the systematic
application of screening instruments reduces false nega-
tive findings, but the specificity and effects on outcome
measures not sufficiently studied [14].
Depression seems to influence the prognosis and even
the survival of cancer patients. For instance, Satin et al.
conducted a meta-analysis with 27 studies on mortality in
cancer patients and depression. A significant effect of de-
pression on mortality was reported (RR: 1.25, P<0.001).
The majority of studies measured the effect of depressive
symptoms and only three of them included patients with
clinical depression. A correlation with disease severity can-
not be excluded [15]. In a large cohort study, patients whohad recently received a cancer diagnosis had an increased
risk for both suicide and death from cardiovascular causes
as compared with controls [16]. Trials found that a de-
crease in severity of depressive symptoms is associated
with a prolongation of survival in cancer patients [17,18].
However, these findings remain controversial as the ma-
jority of studies failed to replicate them [19-22].
Treatment of depression in patients with cancer
The treatment of depression can mainly be divided into
two categories: psychosocial and pharmacological inter-
ventions. A meta-analysis found that cognitive behavioral
therapy has a positive effect on depression and quality of
life in patients with cancer. In the same meta-analysis pa-
tient education had a positive influence on quality of life
but not on depression [23]. A further meta-analysis of psy-
chotherapeutic and psychopharmacological studies found
allover positive effects on depression ratings [24]. Meta-
analyses focusing on pharmacological treatment give a less
consistent picture.
Previous reviews [6,25-28] underpinned the lack of evi-
dence of the adequate effect of pharmacological interven-
tions in the treatment of depression in cancer patients.
However, the reviewed studies were heterogeneous as con-
cerns the studied population (e.g. fatigue or pain as eligibil-
ity criterion and depression as secondary outcome) and the
type of the drug applied (e.g. antidepressants, benzodiaze-
pines, antipsychotics, psychostimulants, etc.). Only limited
conclusions could be drawn from these reviews for the
effectiveness of antidepressants in this population. A meta-
analysis estimated the efficacy of antidepressants in pallia-
tive care (patients with cancer, HIV, COPD, etc.; [29]). The
overall effect of antidepressants was significantly higher
than the effect of placebo. However, only four of the
twenty-five studies included cancer patients. A subgroup
analysis was not performed for each subpopulation and
thus no recommendation can be given for oncological pa-
tients. In another meta-analysis, antidepressants were found
to be effective in the treatment of major depression with a
co-morbid physical illness (RR= 1.42, P<0.0001). Again,
only four RCTs were included that studied cancer patients
with a diagnosis of major depression and no significant ef-
fect of antidepressants on response rates emerged in this
subpopulation (RR=1.26, P=0.19) [30]. In contrast, Hart
et al. [24] found a significant effect on depression ratings in
the subgroup of four pharmacological studies which was
not significantly different from the overall effect of the psy-
chotherapeutic trials. However, this analysis included one
placebo group twice and used Hedge’s g to quantify the re-
sults, which may bias statistics in the pharmacological sub-
group. The authors discuss as a limitation that changes in
questionnaire ratings may have limited clinical relevance.
Depressiveness even without manifest diagnosis of depres-
sion may have adverse effects on prognosis and quality of
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tients should be included in intervention trials and subse-
quent meta-analyses. To overcome the limitations of the
previous analyses, the present systematic review and meta-
analysis focuses on the event of clinical relevant symptom
changes in depressed or depressive patients with cancer.
Methods
Search strategy
The aim of the present study was to determine whether
antidepressants are effective in the treatment of depres-
sion and depressive symptoms in patients with cancer.
The inclusion criteria for the studies were:
1. Double-blind randomized-controlled trials (RCTs),
which could be placebo-controlled or head-to-head
trials. For the purposes of the meta-analysis only
placebo-controlled trials were used.
2. The eligibility criteria of the studies were the
presence of depression or depressive symptoms in
patients with malignancy, i.e. impaired mood had to
be diagnosed by clinical criteria or relevant
depression rating scales.
3. The primary outcome of the studies was reduction
in severity of depression or depressive symptoms.
4. The studies were published in English in the time
between 01.01.1980 and 31.12.2010.
Antidepressants are often used for indications other
than depression (e.g. fatigue, pain, hot flashes) in pa-
tients with malignancy. Thus, we excluded all studies,
which had depression as a secondary outcome only.
We searched for studies in the electronic databases
Pubmed and the Cochrane Library. We aimed towards
higher sensitivity and lower precision in this first selection
in order not to miss an appropriate study. In particular, we
omitted any search term for therapy or treatment, which
could reduce the search sensitivity. This approach is sug-
gested by the “Cochrane Handbook for systematic Reviews
of Interventions” (§6.4.4) [31]. Search terms were: “(de-
pressive OR depression) AND (cancer OR tumor OR neo-
plasm OR lymphoma OR leukemia)”. The applied limits
of the search were 1. articles should be published in the
time between 01.01.1980 and 31.12.2010; 2. articles should
be in English language; and 3. the search term appeared in
the title or the abstract of the articles. We further searched
through the reference lists of reviews and relative articles
to identify any additional studies. Exploratory extensions
of search terms (e.g. including ‘oncology’) did not yield
additional studies.
Article selection and review strategy
The selection of studies involved an initial screening of
the title and the abstract in order to find studies, whichwere appropriate according to the inclusion criteria
stated above. If it was not clear from the title or the ab-
stract that the study should be rejected, the full text was
obtained. The process was conducted independently by
both authors in order to reduce the possibility of rele-
vant articles being rejected.
The data were extracted independently by both authors.
In case of disagreement, a clinician experienced in psycho-
oncology and liaison psychiatry could be involved to medi-
ate consensual decisions. A structured format was used as
the one applied in the presentation of the single studies in
the appendix. Dichotomous data were collected for the
primary outcomes of this review (responders and non-
responders to treatment). Secondary outcomes were the
number of drop outs, the number of patients with adverse
effects, and the quality of life.
Statistical methods (meta-analysis)
A random effects model was applied in the meta-
analysis because of the assumption that the true effect
size was not the same in all studies. Indeed, there were
marked differences between the studies regarding the
type of cancer, the stage of cancer, the drug used in each
study, and the design (intention to treat analysis or com-
pleters’ analysis). The risk ratio (RR with 95% confidence
intervals) was preferred to odds ratio for the computa-
tion of the effect size because it has the advantage of be-
ing more intuitive [32]. Heterogeneity I2 was computed
in order to assess the percentage of the overall variability
attributed to the between studies variability.
The risk of bias in individual studies was evaluated using
the Cochrane Collaboration’ s domain based tool which
assesses allocation concealment, sequence generation,
blinding, selective outcome reporting, and other sources
of bias. Risk of publication bias was assessed using a fun-
nel plot, i.e. a display of estimated study quality in terms
of standard error and the reported effect size. The calcula-
tions were performed using standard formulas [32]
in MicroSoft Excel (Excel 2003 Edition, MicroSoft,
Redmond, CA). The statistical program “Comprehensive
meta-Analysis” (2nd version, Biostat, Englewood, NJ) was
used to create forest and funnel plots.
Results
Search results
The electronic searches yielded 5959 references from
MEDLINE and 1041 references (clinical trials) from the
Cochrane Library. After the initial scanning of the ab-
stracts, a total of 38 reports were detected that may re-
late to drug trials using anti-depressants. Based on the
full-text of these reports, 29 of them were rejected since
they did not reported RCTs on anti-depressant treat-
ment in depressive cancer patients Figure 1. From the
remaining 9 RCTs, 3 studies were head-to-head trials,
7,000 potential relevant references
identified according to the search criteria
6,962 excluded (as irrelevant)
38 articles retrieved in full text
For detailed evaluation
29 excluded (reviews, uncontrolled 
studies- see list in the Appendix)
9 studies included in the review
Figure 1 Flow diagram of the study. The electronic searches
provided a total of 7000 references from MEDLINE and from the
Cochrane Library. After the initial scanning of the abstracts a total of
38 reports remained. These reports were further screened and
assessed for eligibility and 29 of them were rejected. The remaining
9 RCTs fulfilled the inclusion criteria for the review and six of them
fulfilled the criteria for the meta-analysis.
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Thus in total 6 randomized placebo-controlled studies
fulfilled the criteria for this meta-analysis [36-41]. Table 1
provides an overview of the reviewed studies. The
complete list of the assessed trials is presented in
Appendix A.
Previous reviews and meta-analyses exhibited a larger
diversity of study designs [25-28]. For instance, we did
not include 3 trials that had not depression or depressive
symptoms as an eligibility criterion even though the pri-
mary outcome measure was improvement in depression/
depressive symptoms [42-44]. Similarly, we did not in-
clude trials which tested the efficacy of antidepressants
in preventing depressive symptoms in patients with can-
cer [45] or in patients with melanoma undergoing ther-
apy with interferon [46]. Appendix D lists all the 38
trials, which were screened and the reasons for in- or ex-
cluding them.
Review of RCTs in depression
A. Head-to-head trials
Holland et al. [33] studied 38 patients with
depression and breast cancer. The selective
serotonine reuptake inhibitor (SSRI) fluoxetine was
not found to be superior to the tricyclic
antidepressant (TCA) desipramine. Similarly, Pezella
et al. [34] found no significant differences in efficacy
between paroxetine (SSRI) und amitryptiline (TCA)
in a sample of 185 patients with breast cancer. In
contrast, the noradrenergic and specific serotonergic
antidepressant (NaSSA) mirtazapine had a largereffect on depression than imipramine in a sample of
53 cancer patients with depression (Cancurtaran
et al. 2008; [35]).
B. Placebo-controlled studies
Costa et al. [36] and van Heeringen et al. [37]
compared the tetracyclic antidepressant mianserin
with placebo in 73 and 55 patients with
gynecological tumors, respectively. Both publications
reported a significant effect on the observed
depressive symptoms. In contrast, a trial by Razavi
et al. [38] in 91 patients with various types of cancer
did not reveal a significant difference between
fluoxetine and placebo. Similarly, Fisch et al. [39]
failed to demonstrate an advantage of fluoxetine
over placebo in a sample of 163 patients with
advanced cancer. A reevaluation of the results of the
former study with the generalized estimating
equation (GEE) method of regression suggested a
significant effect of the verum as well. Navari et al.
[40] found a significant effect of fluoxetine in 193
depressive patients with breast cancer. Finally,
Musselmann et al. [41] could not document a drug
effect in a trial with a small number of patients
(n= 35) and 3 groups (paroxetine, desipramine,
placebo). For the purposes of the current meta-
analysis, we created a combined intervention group,
which included the patients from both the
paroxetine and the desipramine group, as
recommended in the Cochrane handbook [31].
Meta-analysis
Effect size
All studies defined a measure of response, i.e. what was
considered a meaningful improvement of the depressive
symptoms. The overall effect size in the analysis is
RR=1.56 with 95%-CI: 1.07-2.28 (p= 0.021), i.e. under the
antidepressants a therapeutic response (as defined in the
considered studies) is about 50% more likely than in
the placebo group (see Table 2). A graphical display of the
relative strength of each study is presented in the forest
plot (Figure 2). Four studies found a positive effect of the
antidepressants on depressed cancer patients. In the other
two studies no significant difference emerged but the 95%
confidence intervals were wider than those of the four
other studies (Figure 1). This can be considered as indica-
tive of low precision in the trials with negative finding.
Heterogeneity
The meta-analysis revealed a substantial heterogeneity
I2= 71% with 95% CI: 54%-82%. For a substantial I2
(50-90%), the “Cochrane Handbook for systematic Re-
views of Interventions” [31] recommends a reanalysis
without the outlying studies as part of a sensitivity ana-
lysis. Indeed, the RR of the study by Navari et al. [40] is
Table 1 Overview of the reviewed studies
Author Year Drug Study design Participants (n) Duration Type of
cancer/Stages
Evaluation Results
A. Head-to-head trials
Holland 1998 Fluoxetine vs.
Desipramine
Double blind RCT,
ITT analysis, LOCF
approach
n= 38 6 weeks Breast cancer,
Stages II, III, IV
HDRS Other:
CGI, PGI, HAS,
FLIC, MPAC,
SF-36 HS
No significant difference
between fluoxetine and
desipramine.
Pezella 2001 Paroxetine vs.
Amitriptyline
Double blind RCT,
ITT analysis, LOCF
approach
n= 179 177
received
medication
8 weeks Breast cancer,
any stage
MADRS Other:
CGI, FLIC, PGE
38/88 subjects in the
drug group and 33/87 in
the amitryptiline group
were responders
(p= 0.441)
Cancurtaran 2008 Mirtazapine vs.
Imipramine vs.
Control
groupwithout
medication
Double blind (for
the participants of
the two drug
groups) RCT,
completers’
analysis
n= 53 6 weeks NR SCID, HADS Significant improvement
in the mirtazapine group.
No significant change in
the other two groups.
B. Placebo controlled studies
Costa 1985 Mianserin Double blind RCT,
ITT analysis, LOCF
approach
n= 73 4 weeks Gynecological
cancer, stages
II, III, IV
ZSDRS, HDRS,
CGI-S
28/36 in the Mianserin
group and 18/37 in the
placebo group were
responders (p< 0.025).
Van Heeringen 1996 Mianserin Double blind RCT,
ITT analysis, LOCF
approach
n= 55 7 weeks Breast cancer,
stages I, II
HDRS 19/28 patients in the
mianserin group and
10/27 in the placebo
group were responders
(p= 0.044).
Razavi 1996 Fluoxetine Double blind RCT,
completers’
analysis
n= 91 5 weeks Any kind of
cancer, any
stage
HADS Other:
MADRS, HAS,
SCL-90R, SQOLI
18% in the fluoxetine
group and 20% in the
placebo group were
responders (no significant
difference)
Fisch 2003 Fluoxetine Double blind RCT,
Completers’
analysis
n= 163 12 weeks Any type of
cancer, advanced
stage
TQSS, FACT-G,
BZRDS
Results available for 129
patients. 31/64 patients
in the fluoxetine group
and 23/65 in the placebo
group were responders
(p= 0.12).
Musselmann 2006 Paroxetine vs
Desipramine
vs placebo
Double blind RCT,
ITT analysis, LOCF
approach
n= 35 6 weeks Breast cancer,
any stage
DSM-III-R-
multiaxial
evaluation
HAD, HAS, CGI
5/13 in the paroxetine
group, 5/11 in the
desipramine group and
6/11 in the placebo
group were responders
(no statistical significance).
Navari 2007 Fluoxetine Double blind RCT,
completers’
analysis
n= 193 Six months Breast cancer,
stages I, II
TQSS, BZDRS,
FACT-G
71/90 subjects in the
fluoxetine group and
23/90 in the placebo
group showed a
significant (p< 0.01)
improvement (p< 0.0005).
BZDRS: Brief Zung depression rating scale, CGI-S: Clinical global impression Scale for Severity of Illness, DSM: Diagnostic and statistical manual for mental
disorders, FACT-G: Functional assessment of cancer therapy- global, FLIC: Functional living index- cancer, HAD: Hamilton Depression Scale, HADS: Hospital anxiety
and depression scale, HAS: Hamilton anxiety scale, HDRS: Hamilton rating depression scale, ITT: Intention-to-treat, LOCF: last observation carried forward, MADRS:
Montgomery and Asberg depression rating scale, MPAC: Memorial pain assessment card, NR: Not reported, PGE: Patients’ global evaluation, PGI: Patients’ global
impression, RCT: Randomized controlled trial, SCID: Structured clinical interview for DSM, SF36-HS: Short Form 36 Health survey, SCL-90-R: Symptom Checklist 90,
Revised, SQOLI: Spitzer Quality of Life Index, TQSS: Two questions screening survey, ZSRDS: Zung self-rating depression scale.
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analyses were repeated excluding this study. The effect
of the antidepressants remained significantly better in
comparison to placebo after excluding the outlying study
(RR = 1.39, 95%-CI: 1.09- 1.77, p= 0.008) and theheterogeneity decreased to 10% (95%-CI 0-22%). Hetero-
geneity between 0% and 40% is considered to be of no
importance [31]. This finding confirms that the high het-
erogeneity is most likely due to one outlier which how-
ever does not bias the finding.
Table 2 Number of participants in both groups (drug and placebo) for each study
Author Year Verum Verum Placebo RR
Participants Responders Participants Responders
Costa 1985 Mianserin 36 28 37 18 1.60
Van Heeringen 1996 Mianserin 28 19 27 10 1.83
Razavi 1996 Fluoxetine 45 8 46 9 0.91
Fisch 2003 Fluoxetine 64 31 65 23 1.37
Musselmann 2006 Paroxetine 24 11 11 6 0.84
Navari 2008 Fluoxetine 90 71 90 23 3.09
287 167 276 89
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Four factors differentiating the studies were identified
post-hoc. The selected predictors were: 1. depression vs.
depressive symptoms as eligibility criteria; 2. analysis on
an intention-to-treat (ITT) basis vs. completers’ analysis;
3. inclusion of all or only advanced cancer stages vs. inclu-
sion of only early stages; and 4. the substance group SSRI
vs. tetracyclic antidepressants (mianserin). In this post-hoc
analysis, mianserin had significantly higher RR for re-
sponders than the SSRIs (RRSSRI = 1.16, RRmianserin = 1.67,
Zdifference = −2.17, p= 0.03). In this latter subgroup com-
parison, only the paroxetine group from the study by
Musselmann et al. was contrasted in order to make the
intervention groups comparable. The other predictors did
not significantly influence the RR for antidepressant ef-
fects. Appendix C provides the details of the subgroup
analysis.
Adverse effects and dropouts
There was a substantial amount of missing data
concerning the adverse effects in these studies. Only
three studies reported the total number of patients with
side effects. Four studies provided data about the num-
ber of drop outs because of side effects in each armAuthor RR 95% CI P-Value
Costa 1.60 1.10-2.32 0.014
Van Heeringen 1.83 1.05-3.19 0.032
Razavi 0.91 0.39-2.15 0.827
Fisch 1.37 0.90-2.07 0.138
Musselmann 0.84 0.42-1.68 0.623
Navari 3.09 2.14-4.46 0.000
Total 1.56 1.07-2.28 0.021
Figure 2 Forest plot of RR with CI for all studies and overall. The overa
This means that the effect of antidepressants in this population is significan
the antidepressants on depressed cancer patients. In two studies the antide
studies were wider than the ones of the other four studies, which is indicat(Table 3). Visual inspection suggested no difference.
However due to missing data, we did not perform a
meta-analysis for the adverse effects. All but one studies
provided information about the number of dropouts in
each arm (Table 4). We performed a meta-analysis using
relative risk ratios and found no significant difference
between dropouts in the verum and placebo groups
(mean RR = 0.86, 95%-CI 0.47- 1.56, p = 0.62).
Quality of life
Only three of the six studies included an outcome meas-
ure for quality of life. Razavi et al. [38] used the Spitzer
Quality of Life Index (SQOLI). The increase in the
SQOLI scores was significant in both the drug and the
placebo group, but the difference between the two
groups was not statistically significant. Fisch et al. [39]
used the Functional Assessment of Cancer Therapy-
General (FACT-G, version 3). There was no significant
difference between the fluoxetine and the placebo group
in the proportion of responders (six points change).
Using the generalized estimating equations (GEE)
method of regression (post-hoc), there was a significant
improvement in the total FACT-G scores in the fluoxe-
tine group compared with placebo. Navari et al. [40] alsoRR and 95% CI
Favours placebo Favours drug
ll effect size in the analysis is RR=1.56 with 95%-CI: 1.07- 2.28 (p= 0.021).
t better than the placebo effect. Four studies found a positive effect of
pressant was not better than the placebo. The 95%-CIs of these two
ive of low precision. RR: relative risk; CI: confidence intervals.
Table 3 Number of patients with adverse events
Author Year Drug Verum Placebo
Participants A.E. Participants A.E.
Costa 1985 Mianserin 36 17 37 11
Van Heeringen 1996 Mianserin 28 11 27 17
Razavi 1996 Fluoxetine 45 20 46 23
Fisch 2003 Fluoxetine 64 NR 65 NR
Musselmann 2006 Paroxetine 24 NR 11 NR
Navari 2008 Fluoxetine 90 NR 90 NR
A.E.: adverse event; NR: not reported.
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had a significant improvement in quality of life was sta-
tistically significantly higher in the fluoxetine group as
compared to the placebo group.
Risk for bias and publication bias
The risk of bias for each study can be determined by
assessing the following six domains: 1. sequence gener-
ation, 2. allocation concealment, 3. blinding, 4. missing
data, 5. selective outcome reporting, and 6. other sources
of bias [31]. The group of studies was relative
homogenous and the overall risk for bias could be de-
scribed as “unclear” (Figure 3). The results for every sin-
gle trial are presented in the Appendix B. The risk for
publication bias (i.e. studies with small sample size are
more likely not to be published if their effect is small to
moderate) is assessed by means of the funnel plot, which
displays the relationship between the sample size and
the effect size of the studies. The standard error instead
of the sample size is usually used in the Y axis. No indi-
cation for publication bias can be derived from the
present funnel plot; in particular, there was no gap on
the bottom left side, which would be indicative of un-
published studies with small to moderate effects
(Figure 4).
Discussion
This is the first systematic review with meta-analysis
which focuses exclusively on the psychopharmacological
treatment in cancer patients with depression. TreatmentTable 4 Dropouts
Author Year Verum
Participants Dro
Costa 1985 36
Van Heeringen 1996 28
Razavi 1996 45
Fisch 2003 83
Musselmann 2006 24
216
RR: relative risk.with SSRI or tetracyclic antidepressants was found to
improve depressive symptoms more than placebo. The
small number of studies and patients included, as well as
the questionable risk of bias, however, points out the de-
mand for well-conducted trials before general recom-
mendations can be derived. The diagnosis and treatment
of depression is of high importance in this population of
patients because of the high risk for suicide [16], its im-
pact on the quality of life [2,3], and its influence on anti-
cancer treatment adherence and compliance [47].
Critical for an antidepressive treatment in this group of
patients is a well-funded base of evidence since elevated
risks of adverse effects and interactions must be
expected (see adverse effects and side effects below).
Interestingly in some cancer patients, subsyndromal de-
pressive symptoms (with DSM-IV or ICD-10 diagnosis)
may improve under the antidepressants as well. Direct
comparisons between classical tricyclic antidepressants
and SSRIs revealed no differences in two of the three
reviewed head-to-head trials. The higher effect size of
the tetracyclic agent mianserin in comparison to SSRIs –
as seen in the subgroup analysis – must therefore be
considered exploratory. At this point no specific recom-
mendation concerning effectiveness for a substance class
can be made.
Several studies and meta-analyses have reported on
the effectiveness of antidepressants in patients with de-
pression and physical illness. Van der Feltz-Cornelis
et al. [48] showed in a meta-analysis that pharmaco-
logical interventions are effective in reducing depressivePlacebo RR
pouts Participants Dropouts
7 37 15 0.48
6 27 15 0.39
15 46 7 2.19
19 80 15 1.22
10 11 5 0.92
57 201 57 0.86
Sequence generation
Allocation concealment
Blinding 
Missing Data
Selective Reporting
Other Bias
Yes Unclear No
Figure 3 Risk of bias graph. The semaphore colors provide a visual impression of the quality of the study reports for meta-analysis; green:
condition is fulfilled; yellow: condition is questionable and; red: condition is not fulfilled and risk of bias is present. The allover quality is unclear
and indications for risk of bias can be derived. Therefore the meta-analysis cannot provide a high degree of level of evidence.
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[49] found in another meta-analysis a significant effect
of antidepressants in treating depression in patients with
neurological disorders. There are RCTs which show a
positive effect of SSRIs on depression in patients with
asthma [50,51]. SSRIs were also found to be effective in
the treatment of depression in patients with coronary ar-
tery disease [52]. Although the prevalence of depression
in patients with inflammatory bowel disease (IBD) is
high [1], there are no RCTs which assess the treatment
of depression in this population [53].
Depression and depressive symptoms
There is a trend towards identifying depressive symptoms
instead of trying to define exact diagnoses of concrete de-
pressive syndromes [9,10]. There are also many simple
single- or two-item screening tools, which can detect de-
pression with high specificity and sensitivity. As shown in
the subgroup analysis, patients with depressive symptoms
can benefit from the use of antidepressants exactly like the
patients diagnosed with major depression. On the oneFigure 4 Funnel plot. The funnel plot reveals no gap on the left bottom
studies with larger error and few participants. On the contrary there is a ga
effect because of the small number of studies.hand, this conclusion is of significant clinical importance
because it addresses a practical issue and can motivate
physicians to screen for depression with simple and easy
to use tools. On the other hand, it must be taken into con-
sideration that there was only one study in one of the two
compared groups in the subgroup analysis [39]. The
authors of this study reported a better response in the
patients who had a score higher than 4 in the TQSS,
suggesting that a minimum of symptom severity may be
required for the antidepressive action of antidepressants.
Thus, the results of the subgroup analysis should be
interpreted very carefully and not be misinterpreted as an
excuse for an unreasonable use of antidepressants by phy-
sicians or for the limitation of the role of the consultation-
liaison psychiatry in oncology.
Side effects and interactions
When using an antidepressant, one should pay attention on
possible side effects such as pro-emetic effects of SSRIs and
anticholinergic effects of TCA. Nausea is a common adverse
effect among cancer patients undergoing chemotherapy andsize as an indicative for selective reporting of positive findings in
p on the right size towards the bottom. Conceivably this is a random
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psychiatric conditions such as delirium can also get worse
through the anticholinergic properties of TCAs. Adverse ef-
fects such as agranulocytosis with mianserin [54] should be
taken into consideration in the treatment of cancer patients
who receive chemotherapy.
There are also many interactions between antidepres-
sants and drugs used in the treatment of cancer. The best
studied interactions are these between SSRIs and tamoxi-
fen (a Selective Estrogen Receptor Modulator or SERM),
which is metabolized by CYP2D6 into its active form
endoxifen [55]. Antidepressants such as paroxetine and
duloxetine can inhibit the CYP2D6 cytochrome and thus
the formation of the active metabolite endoxifen [56].
Limitations
The heterogeneity between studies was substantial
(I2= 71% with 95% CI: 54%-82%). As recommended in the
Cochrane guidelines (see above), the meta-analysis was
recalculated excluding an outlying value (as part of a sen-
sitivity analysis). The efficiency remained significant
even after removing an extreme high value (M*= 1.39,
p= 0.008). The heterogeneity fell to 10% which is
considered to be of no importance. Thus, heteroge-
neity affects psychopharmacological studies in cancer
patients. Nevertheless, the overall therapeutic effects
seem to be consistent across studies.
The reliability of these results is limited by the small
number of randomized controlled studies. A larger num-
ber of studies are needed to get safe conclusions. The
small number of studies and participants can be attrib-
uted among other reasons to the preference of the pa-
tients and the clinicians for non-blinded treatment, as
reported by Musselmann et al. [41]. This may explain
the large number of open label studies found in the
search in the databases (which are not presented here).
Another factor which limits the validity of our results is
the quality of the studies. The average risk for bias in
these studies could be described as “unclear.” As shown
in the risk for bias graph (Figure 3), the group of studies
was relatively homogenous as regards to this issue.
Other limitations of this meta-analysis are the use of dif-
ferent depression rating scales and the different response
criteria used by the authors.
Conclusions
Considering the high prevalence of depression and its
impact on mortality and quality of life in cancer patients,
it is a matter of concern that only a few trials assessing
antidepressant efficacy are available. Given this limita-
tion, we found that antidepressants are effective in the
treatment of depression or depressive symptoms in pa-
tients with cancer. A minimum of depressive symptoms’
severity may be required for the patients to benefit fromthe use of antidepressants. Though a larger effect size of
mianserin in comparison to SSRIs in the subgroup ana-
lysis has been shown, no recommendation can be made
for one antidepressant type over another. A quantifica-
tion of tolerability, as ascertained by comparing the
number of patients with adverse effects, was not possible
because of the missing data. The number of drop outs
did not differ significant between the intervention and
the control group.
There are difficulties in defining the diagnosis of clin-
ical depression in cancer patients. Symptoms such as fa-
tigue, sadness, worry, and pain are reported by
depressed patients as well as in patients with advanced
disease. Practical issues such as the ability of physicians
to recognize patients with depression should also be
considered. Reliable single- or two-item questionnaires
have been developed for this purpose. The detection of
depressive symptoms might be more important than the
exact diagnosis of clinical depression. The current meta-
analysis suggests further that antidepressants could be
effective in treating sub-clinical depression. However,
studies with larger samples are needed in order to verify
such conclusion before general clinical recommenda-
tions can be derived.
Appendixes
Appendix A
Listing of the studies
After scanning 7,000 references and screening 38 articles
that seemed appropriate 9 trials could be identified to
fulfill the study inclusion criteria. They were further cat-
egorized into 2 clusters:
A. Head-to-head trials
Three RCTs compared two antidepressants with each
other (head-to-head trials). These studies did not include
a placebo control group.
Holland et al., 1998Number of patients: 40 patients were recruited and
38 ones of these were randomized (21 patients to
the fluoxetine and 17 to the desipramine group).
Type of cancer/Stages: Breast cancer. Stages: II,
III, IV.
Duration: six weeks
Evaluation tools: the Hamilton Depression Rating
Scale (17 item HAM-D), the Clinical and Patient’s
Global Impression scales (CGI and PGI), the
Hamilton Anxiety Rating scale (HAM-A), the
Functional Living Index for Cancer (FLIC),
the Memorial Pain Assessment Card (MPAC) and
the SF-36 Health Survey.
Inclusion criteria: Major depressive episode or
adjustment disorder with depressed mood and
scores over 14 on the first 17 items of HAM-D.
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Table 6 Pezella et al., 2001
Domain Description Review
author’s
judgement
Sequence generation Randomized study, method not
described.
“Unclear”
Allocation
concealment
Double dummy technique was
used. Assignment envelopes are not
described.
“Unclear”
Blinding of
participants, personnel,
and outcome
Double blind study. More frequent
anticholinegic AEs in the
amitriptyline group, which could
break blinding.
“Unclear”
Incomplete
outcome data
Main outcome was the MADRS
score. 16 withdrawals in the
paroxetine group and 19 in the
amitriptyline group. 9 dropouts in
the paroxetine group and 10 in the
amitriptyline group due to AEs.
Other reasons for withdrawals are
not reported. Analysis according to
“No”
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http://www.biomedcentral.com/1471-244X/13/140Response criteria: a statistically significant
baseline to endpoint change in HAM-D.
Design: double blind RCT with ITT analysis,
LOCF approach.
Results: There was a significant improvement in
the HAM-D scores in both group as evidenced by
baseline-to-endpoint changes (p<0.001). ANOVA
showed no significant difference between
fluoxetine and desipramine. Similar improvement
was also observed in the HAM-A. There were no
significant differences in the dropout rates in the
fluoxetine and desipramine group (28.6% and
41.2%, respectively). The only adverse effect
revealing a significance difference was dry mouth
reported by 14 (66.6%) patients in the fluoxetine
group and 4 (23.5%) patients in the desipramine
group.ITT principle. Missing dataPezzela et al., 2001
imputation method: LOCF.
Selective outcome
reporting
Protocol is not available. All pre-
specified outcomes of interest are
reported in the pre-specified way.
“Yes”
Other sources of bias The study appears to be free of
other sources of bias.
“Yes”Number of patients: 179 patients were
randomized into either the paroxetine group (n=
89) or the amitiptyline group (n=90). 88 patients
from the first and 87 from the second group
received medication and were included in the
ITT analysis.
Type of cancer/Stages: Breast cancer, any stage.
Duration: eight weekse 5 Criteria to assess the risk for bias
ain Description Review
author’s
judgement
nce
ation
Describe the method
used to generate the
allocation sequence
Was the allocation
sequence adequately
generated? (Yes, No,
Unclear)
tion
alment
Describe the method
used to conceal the
allocation sequence
Was allocation
adequately concealed?
(Yes, No, Unclear)
ng of
ipants,
nnel, and
me
Describe all measures
used to blind participants
and personnel
Was knowledge of the
allocated intervention
adequately prevented
during the study?
(Yes, No, Unclear)
plete
me data
Describe the
completeness of
outcome data for each
main outcome including
attrition and exclusions
from the analysis.
Were incomplete outcome
data adequately
addressed? (Yes, No,
Unclear)
tive
me
ting
State how the possibility
of selective outcome
reporting was examined
by the review authors
and what was found.
Are reports of the study
free of suggestion of
selective outcome
reporting? (Yes, No,
Unclear)
sources of State any important
concerns about bias not
addressed in the other
domains.
Was the study apparently
free of other problems
that could put it at high
risk of bias?
-wise evaluation of Risk of Bias:
Tabl
Doma
Seque
Alloca
conce
Blindin
partici
and o
Incom
data
Select
report
OtherEvaluation tools: Montgomery and Asberg
Depression Rating Scale (MADRS), the Clinical
Global Impression (CGI), the functional living
index: cancer (FLIC) and the patient’s global
evaluation (PGE).e 7 Holland et al., 1998
in Description Review
author’s
judgement
nce generation Randomized study, randomization
method not described.
“Unclear”
tion
alment
Method is not described. “Unclear”
g of
pants, personnel,
utcome
Double blind study. More frequent
anticholinergic effects in the
fluoxetine group. Issue is not
sufficiently addressed by the authors.
“Unclear”
plete outcome The main outcome war the raw
baseline to endpoint differences in
HAM-D. There were 6 dropouts in
the fluoxetine group, all due to AEs.
There were 7 dropouts in the
desipramine, 4 due to AEs, 3 to
unknown reasons. Analysis
according to ITT principle. Missing
data imputation method: LOCF.
“No”
ive outcome
ing
Study protocol is not available. All
pre-specified outcomes are reported
in the pre-specified way. No
response criteria were defined.
Improvement was not pre-specified.
“No”
sources of bias The study seems to be free from
other sources of bias.
“Yes”
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Table 8 Cancurtaran et al., 2008
Domain Description Review
author’s
judgement
Sequence generation Randomization method is not
described. Patients who refused to
take medication formed a control
group. The allocation by preference
of the participants is problematic in
randomized studies.
“No”
Allocation
concealment
Not described for the two drug
groups. No blinding for the control
group.
“No”
Blinding of
participants, personnel,
and outcome
No blinding for the control group. “No”
Incomplete outcome
data
The main outcome was the HAM-D
score and single symptom scales
score for nausea, pain, vomiting. 4
Dropouts in the mirtazapine group,
4 in the imipramine group, ten
dropouts in the control group. No
ITT analysis. Missing data
imputation method: completers’
analysis.
“No”
Selective outcome
reporting
No study protocol available. All pre-
specified outcomes are reported in
the pre-specified way. No pre-
specified criteria for response or
improvement.
“No”
Other sources of bias The study seems to be free from
other sources of bias.
“Yes”
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ICD-10 criteria for depressive episode and have a
minimum score of 16 in the MADRS.
Response criteria: At least 50% decrease from
baseline in MADRS score
Design: double blind RCT, ITT analysis, LOCF
approach.e 9 Costa et al., 1985
ain Description
nce generation The randomization method is not described.
tion concealment Exact method is not described.
ng of participants,
nnel, and outcome
Double blind trial. The issue is not adequately ad
plete outcome data The main outcome was the HDRS score. 7 drop
placebo group (PG). Reasons for withdrawal: 1 in
efficacy, the treatment by one patient in the PG
MG ended the anticancer treatment, 2 in MG du
to temporary withdrawal from the anticancer tre
were dismissed, 3 in PG had problems at home
Missing data imputation method: LOCF approac
patients were dropouts, which can induce bias i
tive outcome reporting No study protocol available. All pre-specified ou
response criteria are not pre-specified.
sources of bias The study seems to be free of other sources ofResults: 38 patients in the paroxetine group
(43.7%) and 33 patients in the amitriptyline group
(37.8%) were responders (p= 0.441). 47 patients in
the first and 53 from the second group reported
at least one adverse experience. There were 16
withdrawals in the paroxetine group and 19
withdrawals in the amitriptyline group. The study
showed that paroxetine and amitriptyline were
similar in efficacy and tolerability.Cancurtaran et al., 2008
Number of patients: 53 patients participated in
this study: 20 patients in the mirtazapine group,
13 patients in the imipramine group and 20
patients in a control group without medication or
placebo (only supportive psychotherapy).
Type of cancer/Stages: The type and stage of
cancer are not further specified.
Duration: six seeks
Evaluation tools: The patients were screened with
the Structured Clinical Interview for Diagnostic
(SCID). The Hospital Anxiety and Depression
Scale (HADS) was administered for assessment of
depression and anxiety during the study.
Inclusion criteria: Major depressive disorder,
adjustment disorder, anxiety disorders.
Response criteria: The authors reported on the
statistical significance of the rating differences
between baseline and endpoint in each group.
Design: double blind RCT (not blinded for those
who denied medication and received only
psychotherapy), completers’ analysis.
Results: The patients in the mirtazapine group
improved significantly after the six weeks in the
total HADS scores (p=0.014), the anxiety subscale
(p=0.04) and the depression subscale (p=0.008).Review
author’s
judgement
“Unclear”
“Unclear”
dressed. “Unclear”
out in the mianserin group (MG) and 15 in the
each group due to AEs, 2 in PG due to lack of
was interrupted by the investigator, 2 in MG and 4
e to cancer complications, 1 in MG and 2 in PG due
atment, 2 in PG refused anticancer therapy and
and 1 in MG died. The authors used an ITT analysis.
h. Proportionally about one third (30%) of the
n intervention effect estimate.
“No”
tcomes are reported in the pre-specified way. The “No”
bias. “Yes”
Table 10 Van Heeringen et al., 1996
Domain Description Review author’s
judgement
Sequence generation The randomization method is not described “Unclear”
Allocation concealment The exact method is not described. “Unclear”
Blinding of participants,
personnel, and outcome
The study is defined as double blind. The issue is not addressed by the authors. “Unclear”
Incomplete outcome data The main outcome was the HDRS score. There were 6 drop outs in the mianserin group and
15 dropouts in the placebo group. 2 patients in the mianserin group and 11 in the placebo
group withdrew due to lack of efficacy. 2 dropouts in the mianserin group and 4 in the
placebo group due to AEs. ITT analysis. Missing data imputation method: LOCF approach. Over
one third of the patients withdrew from the study (38%), No study protocol available. All pre-
specified outcomes are reported in the pre-specified way.
“No”
Selective outcome reporting No study protocol available. All pre-specified outcomes are reported in the pre-specified way. “Yes”
Other sources of bias The study seems to be free of other sources of bias. “Yes”
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show any significant improvement.
B. Placebo controlled trials
The pharmacological agents that were used in these
six studies were: mianserin (two trials), fluoxetine (three
trials) and paroxetine (one trial). Musselman et al. used
an additional third group with cancer patients receiving
desipramine.
Mianserin
Costa 1985 and van Heeringen 1996 compared
mianserin with placebo. Both reported a significant im-
provement of the depressive symptoms. Mianserin is a
tetracyclic antidepressant agent and is considered as the
predecessor of mirtazapine.
Costa et al., 1985Tabl
Dom
Seque
Alloca
Blindi
perso
Incom
Selec
OtherNumber of patients: 73 patients participated in
this study (36 in the drug group and 37 in the
placebo group).
Type of cancer/Stages: Gynecological cancers,
stages II, III, IVe 11 Razavi et al., 1996
ain Description
nce generation Randomization method is not described.
tion concealment The exact method is not described.
ng of participants,
nnel, and outcome
Double blind trial. The authors do not address thi
plete outcome data The main outcome was the number of patients w
response criteria (≥50% improvement in HADS sc
group (FG) and 7 dropouts in the placebo group
were: 7 due to AEs, 3 decided to interrupt their p
alcohol abuse, and 4 for other reasons:
(Non-compliance, investigator’s decision, lost to fo
were: 2 due to concomitant events, 4 for unknow
authors used an ITT basis for the success and resp
imputation method is not being reported.
tive outcome reporting No study protocol available. All pre-specified outc
sources of bias The study seems to be free of other sources of biDuration: four weeks
Screening/Evaluation tools: Zung Self-Rating
Depression Scale (ZSRDS), Hamilton Depression
Rating Scale. Secondary tools measures: Clinical
Global Impression of Illness Severity (CGI-S).
Inclusion Criteria: ZSRDS over 41 and HDRS
score over 16.
Response criteria: nor reported.
Design: Double blind RCT, ITT analysis, LOCF
approach.
Results: 28 of the 36 patients of the mianserin
group were responders. There were only 18
responders among the 37 participants in the
placebo group (response evaluated according to
the CGI scores). This difference was statically
significant (P<0.025, Chi squared= 6.62). The
primary outcome was based on the scores of
HDRS. There were 7 dropouts in the mianserin
group and 15 in the placebo group. 17 patients
from the drug group and 11 from the placeboReview author’s
judgement
“Unclear”
“Unclear”
s issue. “Unclear”
ith success criteria (HADS score≤8) and with
ore). There were 15 dropouts in the fluoxetine
(PG). The reasons for dropouts in the FG
articipation for unknown reasons, 1 due to
“Unclear”
llow-up). The reasons for dropouts in the PG
n reasons, 1 for psychiatric reasons. The
onse rates. The exact missing data
omes are reported in the pre-specified way. “Yes”
as. “Yes”
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Table 12 Fisch et al., 2003
Domain Description Review author’s
judgement
Sequence generation Randomization by means of a preprinted randomization table. “Yes”
Allocation concealment The exact method is not described. “Unclear”
Blinding of participants,
personnel, and outcome
“The issue is not addressed by the authors. “Unclear”
Incomplete outcome data 163 patients were randomized and 159 allocated to receive medication. The patients were
included in the analysis if they provided data at least two assessments (baseline and one of the
next four). 64 patients were evaluable in the fluoxetine group and 65 in the placebo group.
The reasons for dropouts are not fully presented. The authors used a modification of
completers’ analysis. The missing data imputation method was the best change score, which is
defined as the difference between the baseline score and the average of the best consecutive
scores. According to the authors’ opinion this is a valid statistical method for longitudinal data.
To our opinion the best change score belongs to the inappropriate imputation methods.
“No”
Selective outcome reporting No study protocol available. All pre-specified outcomes are reported in the pre-specified way. “Yes”
Other sources of bias There were many loss of data especially at the fourth assessment. This could influence the
intervention effect estimate.
“No”
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not statistically significant (Chi squared = 2.11).Van Heeringen and Zivkov, 1996
Number of patients: 55 participants in the study
(28 in the mianserin group and 27 in the placebo
group)
Type of cancer/Stages: Breast cancer. Stages I, II
Duration: 7 weeks
Screening tool: Hamilton Depression Rating Scale
(HDRS)
Inclusion Criteria: HDRS score over 16
Response criteria: 50% decrease in baseline HRDS
scores
Design: double blind RCT, ITT analysis, LOCF
approach.
Results: 19 patients from the 28 ones in the
mianserin group and 10 patients from the 27
ones in the placebo group were responders. This
difference was statistically significant (p=0.044,
Fisher’s exact test). Significantly more placeboe 13 Navari et al., 2007
ain Description
nce generation The randomization method is not described.
tion concealment The exact method is not described.
ng of participants,
nnel, and outcome
Double blind trial. The issue is not addressed by t
plete outcome data The main outcome was the scores on FACT-G and
183 were available at the first follow-up and 180 a
not reported. The authors used a completers’ ana
description of the study.
tive outcome reporting The scores of the FACT-G and BZSDS are not repo
patients with significant improvement, which is n
study. The AEs are also not reported.
sources of bias The study seems to be free from other sources oftreated patients (n=15) than mianserin treated
patients (n=6) terminated prematurely the study
(P=0.014, Fisher’s exact test). No significant
differences were found between numbers of
patients complaining of at least one adverse effect
(AE) at any assessment point. At day 42, 11
mianserin- and 17 placebo- treated patients
reported AEs (P=0.14).Fluoxetine
Three RTCs compared fluoxetine with placebo.
Razavi et al., 1996Number of patients: 91 patients participated in
this study (45 in the fluoxetine group and 46 in
the placebo group)
Type of cancer/Stages: Any kind of cancer (mainly
gynecological), any stage (95% without
metastases).
Duration: five weeks
Screening tool: Hospital Anxiety and Depression
Scale (HADS). Other measures: the MontgomeryReview author’s
judgement
“Unclear”
“Unclear”
he authors. “Unclear”
BZSDS. 193 patients enrolled in the study,
t the second. The reasons for dropouts are
lysis, which was not pre-specified in the
“No”
rted. The results are presented as numbers of
ot pre-specified in the description of the
“No”
bias. “Yes”
Fig
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an a
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Table 14 Musselmann et al., 2006
Domain Description Review author’s
judgement
Sequence generation The randomization method is not described “Unclear”
Allocation concealment The exact method is not described. “Unclear”
Blinding of participants,
personnel, and outcome
Double blind study. The issue is not addressed by the authors. “Unclear”
Incomplete outcome data The main outcome was the number of patients with response (≥50% improvement in the
HAM-D scale) and with remission (HAM-D≤7). There were 14 dropouts in a total of 40
participants (40%). Reasons for dropouts were: AEs (2 in paroxetine group, 1 in desipramine
group and 2 in placebo group), lack of efficacy (2 in paroxetine and 2 in placebo group),
patients’ wish to discontinue (2 in placebo group), one was lost to follow-up and one from the
placebo group could not ingest any medication. The analysis was done on an ITT base. The
missing data imputation method was the LOCF.
“No”
Selective outcome reporting No study protocol available. All pre-specified outcomes are reported in the pre-specified way. “Yes”
Other sources of bias Small number of participants. “No”
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Hamilton Anxiety Scale (HAS), the revised
Symptom Checklist (SCL-90R) and the Spitzer
Quality of Life Index (SQOLI).
Inclusion Criteria: a HADS score over 13
Response criteria: a 50% decrease or more in the
baseline HADS scores
Design: double blind RCT, completers’ analysis.
Results: The HADS response rates were 18% in the
fluoxetine group and 20% in the placebo group. The
success rates (HADS scores under 8 at the end of
the trial) were 11% (5 patients) and 7% (3 patients)
in the drug and placebo group respectively. As a
secondary outcome the author reported the
response rates in both groups according to MADRS
scale (50% improvement): these were 31% (14
patients) for the fluoxetine group and 33% (15
patients) in the placebo group. These differences
were not statistically significant. Significantly more
drop outs were observed in the drug group (n=15)
than in the placebo group (n=7) (Chi Square test;
P=0.04). 67% from the fluoxetine group reported at
least one AE compared to 59% in the placebo group
(not statistically significant difference: P= 0.43).3
Unclear
Sequence generation
Allocation concealment
Blinding 
Missing Data
Selective Reporting
Other Bias
Studies (n)
Yes
ure 5 Risk of bias graph for all 9 studies reviewed. Most studies did
cation sequence. All studies were defined as double blind, but the exac
ppropriate method to address the issue of missing data. As one can se
oncerned.Fisch et al., 2003not d
t blind
e theNumber of patients: 163 patients participated in
the study (83 patients in the fluoxetine group and
80 patients in the placebo group).
Type of cancer/Stages: Any type of cancer in
advanced stage.
Duration: twelve weeks
Screening tool: The Two Question Screening
Survey (TQSS) was used to assess mood and
anhedonia. The two questions are: “During the
past month have you been bothered by feeling
down, depressed or hopeless?” and “During the
past month have you been bothered by having
little interest or pleasure in doing things?” There
are five possible answers which are assigned
values from 0 to 4:
0 not at all, 1 a little bit, 2 somewhat, 3 quite a
bit, 4 very much.
For the evaluation of depression and quality of
life in the participants the following tools were
used: the Functional Assessment of Cancer
Therapy General instrument (FACT-G), the
Functional Assessment of Chronic Illness
Therapy Spiritual and the Brief Zung Self6 9
No
escribe the methods used to generate and conceal the
ing method was not described in any of them. No study used
studies were relative uniform as far as the issue of risk of bias
Tabl
Auth
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Total
Grou
Fisch
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RR(A) =
Table 15 Subgroup analysis for inclusion criteria
Author Year Verum Verum Placebo
Participants Responders Participants Responders
Group A: Clinical depression as an inclusion criterion
Costa 1985 Mianserin 36 28 37 18
Van Heeringen 1996 Mianserin 28 19 27 10
Razavi 1996 Fluoxetine 35 8 46 9
Musselmann 2006 Paroxetine/desipramine 24 11 11 6
Total 133 66 121 43
Group B: Clinical depression not as an inclusion criterion
Fisch 2003 Fluoxetine 64 31 65 23
Total 64 31 65 23
RR(A)= 1.42, RR(B)= 1.37 (Zdiff= 0.19, p=0.85).
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with 11 items.
Inclusion Criteria: A TQSS score of 2 or greater.
Patients with a major depressive episode were
excluded.
Response criteria: A best change score of at least −3
in the BZDRS. A best change score is defined as
the difference between the baseline score and the
average of the best consecutive scores.
Design: Double blind RCT. Computations were
made only on patients who completed the
baseline questionnaires (n=159) and at least one
follow up assessment (n=129). The authors used
additionally the generalized estimating equation
(GEE) method of regression.
Results: There were data for 129 patients at the
end point (64 in the fluoxetine group and 65 in
the placebo group). 48% (n=31) patients in the
fluoxetine group and 36% (n=23) in the placebo
group were responders. This difference was not
statistically significant. Reevaluating the data with
the GEE method of regression the authors founde 16 Subgroup analysis for study design (ITT vs. completers’ a
or Year Drug
Participant
p A: Analyses by ITT
1985 Mianserin 36
eeringen 1996 Mianserin 28
lmann 2006 Paroxetine/desipramine 24
88
p B: analyses not by ITT
2003 Fluoxetine 64
i 1996 Fluoxetine 45
109
tention to treat.
1.49, RR (B) = 1.27 (Zdiff= 0.93, p= 0.36).a significant improvement in the fluoxetine
group. There were not any concrete data about
the number of dropouts or reported adverse
effects in each group.Navari et al., 2008
Number of patients: 203 patients out of the 357
screened patients qualified for enrolment in this
study. From the 193 who enrolled in the study
the authors reported on the 180 patients who
completed the six month assessment.
Type of cancer/Stages: Breast cancer, stages I, II
Duration: six months
Screening tool: The Two Question Screening
Survey (TQSS) was used to assess mood and
anhedonia. The two questions are: “During the past
month have you been bothered by feeling down,
depressed or hopeless?” and “During the past month
have you been bothered by having little interest or
pleasure in doing things?” There five possible
answers which are assigned values from 0 to 4:
0 not at all, 1 a little bit, 2 somewhat, 3 quite a
bit, 4 very much.nalysis)
Verum Placebo
s Responders Participants Responders
28 37 18
19 27 10
11 11 6
58 75 34
31 65 23
8 46 9
39 111 32
Tabl
Auth
Grou
Fisch
Razav
Musse
Total
Grou
Costa
Van H
Total
RR(A)=
Table 17 Subgroup analysis for cancer stage
Author Year Drug Verum Placebo
Participants Responders Participants Responders
Group A: Any or advanced cancer stage
Costa 1985 Mianserin 36 28 37 18
Fisch 2003 Fluoxetine 64 31 65 23
Razavi 1996 Fluoxetine 45 8 46 9
Musselmann 2006 Paroxetine/desipramine 24 11 11 6
Total 169 78 159 56
Group B: Early cancer stages
Van Heeringen 1996 Mianserin 28 19 27 10
Total 28 19 27 10
RR(A)= 1.29, RR(B)= 1.83 (Zdiff= − 1.73, p=0.11).
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Functional Assessment of Cancer Therapy-
General (FACT-G) and the depression was
estimated with the Brief Zung self administered
Depression Rating Scale (BZDRS).
Inclusion Criteria: A TQSS score of 2 or greater.
Patients with a major depressive episode were
excluded.
Response criteria: “significant improvement” in
the BZSRS (not further defined).
Design: double blind RCT, completers’ analysis.
Results: 71 patients from the fluoxetine group and
23 patients from the placebo group had a
significant improvement in depressive symptoms
(P<0.0005). There were not any data about
adverse effects.Paroxetine
One study compared paroxetine with desipramine and
placebo in depressed cancer patients.
Musselman et al., 2006Number of patients: 35 patients participated in
this study. They were divided into three groupse 18 Subgroup analysis for type of antidepressant
or Year Drug Ver
Participants
p A: SSRIs
2003 Fluoxetine 64
i 1996 Fluoxetine 45
lmann 2006 Paroxetine 13
122
p B: Mianserin
1985 Mianserin 36
eeringen 1996 Mianserin 28
64
1.16, RR(B)= 1.67 (Zdiff= −2.17, p= 0.03).and assigned to receive either paroxetine (n=13)
or desipramine (n=11) or placebo (n=11).
Type of cancer/Stages: Breast cancer at any stage.
Duration: six weeks
Screening tool: a DSM-III-R multi-axial
evaluation. Other rating scales used were the 21-
item Hamilton Rating Scale for Depression
(HAM-D), the 14-item Hamilton Rating Scale for
Anxiety and the Clinical Global Impression Scale
(CGI).
Inclusion Criteria: DSM-III-R criteria for major
depression (except duration of illness had to be at
least on month), HAM-D score of at least 14 in
the first 17 items of the 21-item HAM-D.
Response criteria: A decrease of ≥50% from
baseline HAM-D score or a CGI global
improvement score ≤−2. Clinical remission was
defined as a HAM-D score ≤7.
Design: double blind RCT, ITT analysis, LOCF
approach
Results: The response rates were: 38% (5/13
patients) in the paroxetine group, 45% (5/11um Placebo
Responders Participants Responders
31 65 23
8 46 9
5 11 6
44 122 38
28 37 18
19 27 10
47 64 28
Table 19 List of the final 38 studies
Article Assessment
Goldberg RJ. Management of depression in the patient with advanced cancer.
JAMA.246(4):373–6, 1981.
Review
Costa D, Mogos I, Toma T. Efficacy of mianserin in the treatment of depression of
women with cancer. Acta Psychiatrica Scandinavica. 72 (suppl. 320): 85–92, 1985.
RCT included in the review
Mathé G, Lopez MD, Fréchet M, de Vassal F, Brienza S, Gastiaburu J. A
comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for
the search of the most rapidly and frequently active treatment of depressive
syndromes in an oncology service. Biomedicine and Pharmacotherapy.
41(1):13–26, 1987.
No double blind RCT
Maguire P, Hopwood P, Tarrier N, Howell T. Treatment of depression in cancer
patients. Acta Psychiatrica Scandinavica Suppl. 320:81–4, 1985.
Antidepressant therapy was administrated
together with anxiolytic and supportive psychotherapy
Evans DL, McCartney CF, Nemeroff CB, Haggerty JJ Jr, Simon JS, Pedersen CA,
Holmes V, Droba M, Mason GA, Raft D, et al. Depression in cancer patients.
Diagnostic and treatment considerations. North Carolina Medical Journal.
49(10):546–8, 1988.
Review
Silberfarb PM. Psychiatric treatment of the patient during cancer therapy.
CA; A Cancer Journal of Clinicians. 38(3):133–7, 1988.
Review
Evans DL, McCartney CF, Haggerty JJ Jr, Nemeroff CB, Golden RN, Simon JB,
Quade D, Holmes V, Droba M, Mason GA, et al. Treatment of depression in
cancer patients is associated with better life adaptation: a pilot study.
Psychosomatic Medicine. 50(1):73–6, 1988.
No control group.
Van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer
patients. A placebo controlled study of Mianserin. British Journal of Psychiatry.
169: 440.443, 1996.
RCT included in the review
Razavi D, Allilaire JF, Smith M, Salimpour A., Verra M, Desclaux B, Saltel P, Piollet I,
Gauvain-Piquard A., Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth
JP, Bouhassira M, Mesters P, Blin P. The effect of fluoxetine on anxiety and
depression symptoms in cancer patients. Acta Psychiatrica Scandinavia.
94: 205–210, 1996.
RCT included in the review
Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial
of fluoxetine and desipramine in depressed women with advanced cancer.
Psycho-Oncology. 7: 291–200, 1998
RCT included in the review
Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N. Comparative study of
the efficacy and safety of trazodone versus clorazepate in the treatment of
adjustment disorders in cancer patients: a pilot study. The Journal of International
Medical Research. 27(6):264–72, 1999.
The efficacy of trazodone cannot be safely proven when it is
compared to a benzodiazepine. Depression was not an eligibility
criterion.
Musselmann DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS,
Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression
induced by high dose interferone alpha. The New England Journal of Medicine.
Vol 344, No 13, 2001
Prevention study, thus prevention was not an eligibility criterion.
Pezella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients
with breast cancer: a comparison between paroxetine and amitrptyline. Breast
Cancer Research and Treatment. 70: 1–10, 2001
RCT included in the review
Passik SD, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Edgerton S, Dugan W.
Use of a depression screening tool and a fluoxetine-based algorithm to improve
the recognition and treatment of depression in cancer patients. A demonstration
project. Journal of Pain and Symptom Management. 24(3):318–27, 2002.
No RCT.
Carr D, Goudas L, Lawrence D, Pirl W, Lau J, DeVine D, Kupelnick B, Miller K.
Management of cancer symptoms: pain, depression, and fatigue. Evidence
Report/Technology Assessment. 61:1–5, 2002.
Review.
Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms
associated with advanced cancer: olanzapine and mirtazapine. A World Health
Organization project. Expert Review of Anticancer Therapy.
2(4): 365–76, 2002.
Recommendation
Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen SH, Arquette MA, Brames
MJ, Einhorn LH. Fluoxetine versus Placebo in advanced cancer outpatients: a
double-blinded trial of the Hoosier oncology group. Journal of Clinical Oncology.
Vol 21, No 10: 1937–1943, 2003.
RCT included in the review
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Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open label pilot
study of citalopram for depression and boredom in ambulatory cancer patients.
Palliat Support Care. 2003 Mar;1(1):71–7.
No RCT.
Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ, Hynes HE,
Banerjee TK, Kirschner JJ, King DK. Differential effects of paroxetine on fatigue
and depression: a randomized, double blind trial from the University of Rochester
Cancer Center Community Clinical Oncology Program. Journal of Clinical
Oncology. Vol 21, No 24: 4635–4641, 2003
Depression was not an eligibility criterion
Pae CU, Kim YJ, Won WY, Kim HJ, Lee S, Lee CU, Lee SJ, Kim DW, Lee C, Min WS,
Kim CC, Paik IH, Serretti A. Paroxetine in the treatment of depressed patients with
haematological malignancy: an open-label study. Human Psychopharmacology.
19(1):25–9, 2004.
No RCT.
Coyne JC, Palmer SC, Shapiro PJ. Prescribing antidepressants to advanced cancer
patients with mild depressive symptoms is not justified. Journal of Clinical
Oncology. 1;22(1):205–6; author reply 206–8, 2004.
Comment.
Thangathurai D, Roffey P, Mogos M, Riad M, Mikhail M. Usefulness of
desipramine in ICU cancer patients for acute depression. Journal of Palliative
Care. 20(4):326, 2004.
Comment.
Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the
treatment of depressive and vasomotor symptoms in women with
perimenopausal depression. Depression and Anxiety. 22(2):94–7, 2005.
No RCT.
Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE,
Bushunow P, Qazo R, Smith B. Effect of paroxetine hydrochloride on fatigue
and depression in breast cancer patients receiving chemotherapy. Breast Cancer
Research and Treatment. 89: 243–249, 2005.
Depression was not an eligibility criterion.
Musselmann DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S,
Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB. A double-
blind multicenter parallel-group study of paroxetine, desipramine or placebo in
breast cancer patients (stages I, II, III, IV) with major depression. Journal of Clinical
Psychiatry. 67: 288–296, 2006.
RCT included in the review.
Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-
blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment
of hot flashes in women with early stage breast cancer taking tamoxifen.
The Breast Journal. 12(2):114–22, 2006.
Depression was a secondary outcome.
Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects
of bupropion SR on fatigue, depression and quality of life of mixed-site cancer
patients and their partners. Psychooncology. 15(3):259–67, 2006.
No RCT.
Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M.
Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer
patients--a double-blind, randomized study. Annals of Oncology.
18(4):689–93, 2007.
No measures for depression were included.
Stockler MR, O´Connel R, Nowak AK, Goldstein D, Turner J, Wilcken NRC, Wyld D,
Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB,
Simes RJ. Effect of sertraline on symptoms and survival in patients with advanced
cancer, but without major depression: a placebo controlled double-blind
randomized trial. Lancet Oncology. 8: 603–612, 2007.
Depression was not an eligibility criterion.
Raji MA, Barnum PD, Freeman J, Markowitz AB. Mirtazapine for depression and
comorbidities in older patients with cancer. Annals of Pharmacotherapy.
41(9):1548–9, 2007.
No RCT.
Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Tuhan L, Alkis N. Mirtazapine
improves sleep and lowers anxiety and depression in cancer patients: superiority
over imipramine. Supportive Care in Cancer. 16: 1291–1298, 2008.
RCT included in the review.
Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed
oncological patients. Supportive Care in Cancer. 16(1):83–91, 2008.
No RCT.
Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y. Clinical
experience of the use of a pharmacological treatment algorithm for major
depressive disorder in patients with advanced cancer. Psychooncology.
17(2):154–60, 2008.
No RCT.
Ersoy MA, Noyan AM, Elbi H. An open-label long-term naturalistic study of
mirtazapine treatment for depression in cancer patients. Clinical Drug
Investigation. 28(2):113–20, 2008.
No RCT.
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Kim SW, Shin IS, Kim JM, Kim YC, Kim KS, Kim KM, Yang SJ, Yoon JS. Effectiveness
of mirtazapine for nausea and insomnia in cancer patients with depression.
Psychiatry and Clinical Neuroscience. 62(1):75–83, 2008.
No RCT.
Lydiatt WM, Denman D, McNeilly DP, Puumula SE, Burke WJ. A randomized
placebo- controlled trial of citalopram for the prevention of major depression
during treatment for head and neck cancer. Archives of Otolaryngology- Head
and Neck Surgery. Vol. 134 (No 5), 2008.
Prevention study, thus depression was not an eligibility criterion.
Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in
patients with early stage breast cancer undergoing adjuvant therapy. Breast
Cancer Research and Treatment. 112: 197–201, 2008.
RCT included in the review.
Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients
with cancer with low doses of ketamine and desipramine. Journal of Palliative
Medicine. 13(3):235, 2010.
The authors report on two patients
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patients) in the placebo group (p= 0.91). The
remission rates were: 23% (3/11 patients) in the
paroxetine group, 45% (5/11 patients) in the desi-
pramine group and 36% (4/11 patients) in the
placebo group (p=0.55). There were 14 dropouts
by week six: 5 in the paroxetine group, 4 in the
desipramine group and 5 in the placebo group.The most common adverse effects were:
Paroxetine: dry mouth (n=6), nausea (n=5), pain (n=5)
Desipramine: dry mouth (n=8), constipation (n=4),
headaches (n=4), pain (n=4)
Placebo: headache (n=5), pain (n=5), dry mouth (n=3),
constipation (n=3).
The difference in side effects among the groups was
not significant.
Appendix B
Assessment of bias
We used the Cochrane Collaboration’s tool for assessing
the risk of bias. These criteria may be considered suffi-
ciently strict. This included extracting of six domains
and judging them. The consensual authors’ judgment
were either “Yes”, indicating low risk of bias, “No” indi-
cating high risk of bias, or “Unclear” indicating unknown
risk of bias. The criteria to assess the studies were:
(Tables 5, 6, 7, 8, 9, 10, 11, 12, 13, 14).
In summary, only one study (Fisch et al., 2003) de-
scribed the exact randomization method. The rest studies
defined themselves as randomized, but did not describe
the method (“Unclear”). The exact allocation concealment
method was not described in any study. All studies were
defined as double blind. No article reported which persons
in the study were blinded and which were not. All but one
studies described an inappropriate missing data imput-
ation method, even the ones who used an ITT-based ana-
lysis; the LOCF method can also introduce bias (see
Cochrane [31] and www.missingdata.org.uk). In totalseveral indications for Risk of Bias can be observed and
most items remained unclear (see Figures 3 and 5).
Appendix C
Subgroup analysis after outlier exclusion
1. Eligibility criteria: Depression vs. depressive symptoms
Subgroup analysis for inclusion criteria (Table 15).
2. Study design: Intention to treat vs. completers’ analysis
Subgroup analysis for study design (ITT vs. com-
pleters’ analysis) (Table 16)
3. Eligibility criteria: Cancer stage
Subgroup analysis for cancer stage (Table 17).
4. Comparison between SSRIs and tetracyclic
antidepressants
Subgroup analysis for type of antidepressant (Table 18)
Appendix D
List of the final 38 studies (Table 19)
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